



## SVB Securities Serves as Exclusive Financial Advisor to AMF Medical SA on its Sale to Tandem Diabetes Care, Inc. (Nasdaq: TNDM)

CHF to USD conversion rate of 1.07 as of 12/12/2022.

### Key Transaction Highlights

- On December 13<sup>th</sup>, Tandem Diabetes Care, Inc. ("Tandem"), a global insulin delivery and diabetes technology company, announced its definitive agreement to acquire AMF Medical SA ("AMF Medical"), a privately-held development-stage Swiss developer of the Sigi<sup>TM</sup> Patch Pump ("Sigi<sup>TM</sup>").
- The aggregate purchase price consists of a cash upfront payment of CHF 70.4 million (\$75.3 million), which includes a previous strategic investment of CHF 8 million (\$8.6 million), and contingent earnout payments of up to CHF 129.6 million (\$138.6 million).
- AMF Medical's proprietary and disruptive insulin delivery solution is expected to:
  - Expand Tandem's type 1 and type 2 addressable market opportunities by adding a new product designed for a segment of people living with diabetes not served by Tandem today.
  - Accelerate time-to-market for a patch pump in Tandem's portfolio of technology offerings.
  - Further Tandem's sustainability objectives by offering an additional pump that minimizes the generation of electronic and battery waste.
  - Provide a pathway for channel expansion and increased customer access.
- The transaction is subject to the satisfaction of customary closing conditions and is expected to close in January 2023.
- SVB Securities acted as exclusive financial advisor to AMF Medical.

### About AMF Medical

Originally founded in 2014 in the Swiss Medtech Valley, AMF Medical is developing a novel technology to address the unmet needs of people on insulin therapy. The company's flagship product, Sigi<sup>TM</sup>, is a next-generation interoperable, semi-reusable and rechargeable patch pump, that uses standard pre-filled insulin cartridges. It is designed to make life easier for people with diabetes. Sigi<sup>TM</sup> received Breakthrough Device Designation by the FDA in November 2021. The device is intended for prescription-use only and has not yet been FDA-cleared nor CE-marked. AMF Medical is led by Co-CEOs Mr. Pim van Wesel and Mr. Antoine Barraud, PhD who is also a Co-Founder. Diabetes industry experts John Timberlake and Peter Gerhardtsson serve on the company's Board of Directors.

### About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company's human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology.

If you would like to unsubscribe from this distribution, click [here](#). If you would like to unsubscribe from all SVB Securities distributions, click [here](#).

THIS EMAIL IS FOR INFORMATIONAL PURPOSES ONLY AND IS BEING FURNISHED TO INVESTMENT BANKING CLIENTS OF SVB SECURITIES LLC. THE INFORMATION INCLUDED HEREIN IS FOR YOUR INFORMATION ONLY AND MAY NOT BE REPRODUCED FOR OR REDISTRIBUTED TO ANY OTHER PURPOSES. THIS EMAIL IS NOT AN OFFER TO SELL, AND IS NOT SOLICITING AN OFFER TO BUY, ANY SECURITIES.

**BOSTON**

53 State Street  
40th Floor  
Boston, MA 02109

**CHARLOTTE**

2151 Hawkins Street  
Suite 1025  
Charlotte, NC 28203

**NASHVILLE**

40 Burton Hills Boulevard  
Suite 200  
Nashville, TN 37215

**NEW YORK**

1301 Avenue of the Americas  
12th Floor  
New York, NY 10019

**SAN FRANCISCO**

255 California Street  
12th Floor  
San Francisco, CA 94111